PacBio PACB recently announced a strategic collaboration with Chulalongkorn University, one of Thailand’s foremost institutions in genomic and translational research, to implement PacBio’s HiFi whole genome sequencing (WGS) as part of the newborn screening research program. This initiative marks the first population-scale deployment of PacBio’s HiFi technology in the Asia Pacific region. It is designed to evaluate how comprehensive genomic data can enable earlier and more accurate identification of rare, treatable conditions in newborns.
By integrating PacBio’s advanced long-read sequencing capabilities, the program will help uncover a broader spectrum of genetic variants that often go undetected with traditional screening methods. Through this effort, PacBio and Chulalongkorn University aim to build a scalable model that could transform early-stage diagnostics and public health planning on a global scale.
Likely Trend of PACB Stock Following the News
Following the announcement, shares of the company closed flat at $1.12 on Friday. In the year-to-date period, PACB’s shares have lost 38.8% compared with the industry’s 10.1% decline. The S&P 500 decreased 4.4% in the same time frame.
This collaboration positions PacBio at the forefront of a major shift in global healthcare, signaling growing adoption of its HiFi sequencing technology for large-scale clinical applications. By demonstrating real-world utility in a critical use case, such as newborn screening, PacBio not only expands its footprint in the fast-growing Asia Pacific region but also builds a compelling case for broader international adoption. Successful implementation could lead to long-term revenue growth from government contracts, public health partnerships, and increased demand for HiFi systems, reinforcing investors’ confidence in the scalability and relevance of PacBio’s platform in precision medicine.
Meanwhile, PACB currently has a market capitalization of $336.1 million. The company expects its earnings to grow 13.1% in 2025.
Zacks Investment Research
Image Source: Zacks Investment Research
More on PACB’s Collaboration
The collaboration between PacBio and Chulalongkorn University is a landmark initiative that highlights the transformative potential of WGS in public health. Traditional newborn screening programs typically rely on targeted panels to detect a limited number of conditions, often missing rare or complex genetic disorders. PacBio’s HiFi WGS, by contrast, delivers highly accurate, long-read genomic data that captures regions of the genome inaccessible to short-read technologies. This includes structural variants, repeat expansions, and epigenomic information, all of which are critical for identifying a wider spectrum of genetic risks from birth. By enabling a more complete and precise view of the newborn genome, the technology opens the door to earlier diagnosis and intervention for conditions that might otherwise remain undetected until much later in life.
Chulalongkorn University, through its Center of Excellence for Medical Genomics, is likely to bring deep expertise and infrastructure to the table, making it an ideal partner for this endeavor. The university aims to build a robust and scalable research model that can be replicated across other national health systems. This research-driven approach not only enhances clinical care but also contributes to public health data systems, laying the groundwork for informed policy decisions, better resource allocation, and eventually, personalized healthcare strategies on a national scale.
On a broader level, this initiative positions Thailand as a leader in precision medicine within the Asia Pacific region and places PacBio at the center of a growing global movement toward genome-informed healthcare. By successfully deploying HiFi WGS in a population-scale screening program, PacBio is setting a benchmark for how advanced sequencing technologies can be integrated into public health. This could catalyze similar initiatives in other countries, unlocking new markets and reinforcing PacBio’s reputation as a pioneer in genomic innovation. With increasing recognition of genomics as a foundational tool in early disease detection and prevention, this collaboration not only accelerates scientific progress but also enhances PacBio’s long-term commercial and strategic outlook.
PACB’s Favorable Industry Prospects
Per a report by Grand View Research, the global whole genome sequencing market size was estimated at $2.12 billion in 2024 and is expected to witness a CAGR of 22.17% from 2025 to 2030.
The WGS market is experiencing significant growth, driven by a confluence of technological advancements, decreasing costs, and a growing demand for personalized medicine. Several key factors contribute to this expansion, transforming the landscape of genomics and impacting various sectors, including healthcare, research, and agriculture.
PACB’s Zacks Rank & Stocks to Consider
PACB carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX.
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted EPS of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CVS Health has a long-term estimated growth rate of 11.4%. CVS’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
